Vol 25, No 1 (2019)
Articles
Published online: 2019-03-20
The place of heparins in the treatment of venous thromboembolism
DOI: 10.5603/AA.2019.0006
Acta Angiologica 2019;25(1):35-40.
Abstract
Venous thromboembolism, in the form of lower limb deep vein thrombosis and its most dangerous complication
that is a pulmonary embolism, is a common disease with an increasing incidence associated with the ageing
population. The scheme of VTE treatment underwent changes when a new drug group — directly and selectively
acting oral anticoagulants — was introduced. However, the scope of VTE therapy with parenterally administered
low-molecular-weight heparins was wide, i.e., they produced vast progress in the disease’s treatment in the 1980s.
Keywords: venous thromboembolismlow-molecular-weight heparinenoxaparindeep vein thrombosispulmonary embolism
References
- Praca zbiorowa. Polskie Wytyczne Profilaktyki i Leczenia Żylnej Choroby Zakrzepowo-Zatorowej. Medycyna Praktyczna. Wyd. specjalne. 2012.
- Robertson L, Kesteven P, McCaslin JE, et al. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database Syst Rev. 2015(6): CD010956.
- Huerta C, Johansson S, Wallander MA, et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med. 2007; 167(9): 935–943.
- Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000; 160(6): 761–768.
- Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007; 92(2): 199–205.
- Tagalakis V, Patenaude V, Kahn SR, et al. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013; 126(9): 832.e13–832.e21.
- Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e419S–e496S.
- Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003; 349(13): 1227–1235.
- Bates SM, Jaeschke R, Stevens SM, et al. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e351S–e418S.
- Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010; 8(11): 2450–2457.
- van der Hulle T, Cheung WY, Kooij S, et al. YEARS study group. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet. 2017; 390(10091): 289–297.
- Zawilska K, Jaeschke R, Tomkowski W, et al. Polskie wytyczne profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej. Medycyna Praktyczna, Wyd. specjalne. 2009; 1: 1–55.
- National Institute for Health and Care Excellence. CG92: Venous thromboembolism— reducing the risk. 2010. http://guidance.nice.org.uk/CG92 (1.05.2014).
- Weitz JI. New oral anticoagulants: a view from the laboratory. Am J Hematol. 2012; 87 Suppl 1: S133–S136.
- Hass B, Pooley J, Harrington AE, et al. Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management. Thromb J. 2012; 10(1): 24.
- Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e44S–e88S.
- Charakterystyka produktu leczniczego Neoparin. http://www.urpl.gov.pl/pl.
- Samama MM, Desnoyers PC. Low molecular weight heparins: an overview. Thrombosis, Scientic and Clinical Prospectives. 1995; 5: 95–106.
- Lim W, Dentali F, Eikelboom JW, et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006; 144(9): 673–684.
- Szczeklik A. Choroby wewnętrzne. Kompendium medycyny praktycznej 2010. Wydanie II zaktualizowane i rozszerzone. Medycyna Praktyczna, Kraków 2010.
- Qaseem A, Snow V, Barry P, et al. Joint American Academy of Family Physicians/American College of Physicians Panel on Deep Venous Thrombosis/Pulmonary Embolism, Joint American Academy of Family Physicians/American College of Physicians Panel on Deep Venous Thrombosis/Pulmonary Embolism. Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Fam Med. 2007; 5(1): 57–62.
- Previtali E, Bucciarelli P, Passamonti SM, et al. Risk factors for venous and arterial thrombosis. Blood Transfus. 2011; 9: 120–38.
- Coppola R, Mari D, Lattuada A, et al. Von Willebrand factor in Italian centenarians. Haematologica. 2003; 88(1): 39–43.
- Wilkerson WR, Sane DC. Aging and thrombosis. Semin Thromb Hemost. 2002; 28(6): 555–568.
- Melis F, Vandenbrouke JP, Büller HR, et al. Estimates of risk of venous thrombosis during pregnancy and puerperium are not influenced by diagnostic suspicion and referral basis. Am J Obstet Gynecol. 2004; 191(3): 825–829.
- Cunningham FG, Leveno KL, Bloom SL. Thromboembolic disorders. In: Cunningham FG, Leveno KL, Bloom SL. ed. Williams obstetrics. McGraw & Hill, New York 2005.
- Sajdak S, Rybak Z, Oszkinis G. Wytyczne profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej w ciąży. Przeg. Gin. Poł. 2006; 6(4): 205–216.
- McLintock C. Anticoagulant choices in pregnant women with mechanical heart valves: Balancing maternal and fetal risks – the difference the dose makes. Thrombosis Research. 2013; 131: S8–S10.
- Vitale N, De Feo M, De Santo LS, et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol. 1999; 33(6): 1637–1641.
- Trojnarska O, Plaskota K. Leczenie przeciwkrzepliwe w czasie ciąży u kobiet z implantowanymi protezami zastawkowymi. Kardiol Pol. 2012; 70: 622–626.
- Lyman GH, Khorana AA. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009; 27(29): 4821–4826.
- Lee A.Y. Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. Hematology Am. Soc. Hematol. Educ. Program 2010: 144–149.J. Hirsh, G. Guyatt, G.W. Albers, R. Harrington, H.J. Schunemann American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition): Antithrombotic and Thrombolytic Therapy 8th Ed: ACCP Guidelines Chest, 133 (2008), 71-105 2008.
- Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166(4): 458–464.
- Wojtukiewicz M, Sierko E, Tomkowski W, et al. Wytyczne dotyczące profilaktyki i leczenia żylnej choroby zakrzepowo- -zatorowej u chorych na nowotwory poddawanych leczeniu zachowawczemu. Onkologia w praktyce klinicznej — edukacja. 2006; 2: 73–101.
- Zawilska K, Zawilska K. Praktyczne aspekty leczenia żylnej choroby zakrzepowo-zatorowej. Hematologia. 2017; 7(3): 231–242.
- Ageno W, Beyer-Westendorf J, Garcia DA, et al. Guidance for the management of venous thrombosis in unusual sites. J Thromb Thrombolysis. 2016; 41(1): 129–143.
- Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e326S–e350S.
- Spyropoulos AC, Turpie AGG, Dunn AS, et al. REGIMEN Investigators. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost. 2006; 4(6): 1246–1252.
- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2): 315–352.